

20 Aug 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a look at global executive compensation; Pfizer's new myeloma approval; Merck & Co. and Kelun trump ADC breast cancer success; combo Alzheimer's therapies in Eisai's pipeline; and a look at the state of gene therapy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 August 2023, including: a look at global executive compensation; [Pfizer Inc.](#)'s new myeloma approval; [Merck & Co., Inc.](#) and [Sichuan Kelun Pharmaceutical Co Ltd.](#) trump ADC breast cancer success; combo Alzheimer's therapies in [Eisai Co., Ltd.](#)'s pipeline; and a look at the state of gene therapy.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Titans Of Pharma: Pfizer's Bourla Tops Big Pharma CEO Compensation League](#)" - Scrip, 16 Aug, 2023.)

(Also see "[Pfizer Touts Elrexio's Potential For Community Oncology Use In Myeloma](#)" - Scrip, 15 Aug, 2023.)

(Also see "[Merck & Co's TROP2 Partner Trumpets Phase III Success In TNBC](#)" - Scrip, 14 Aug, 2023.)

(Also see "[Eisai's Alzheimer's Pipeline Offers Combination Therapy Potential](#)" - Scrip, 14 Aug, 2023.)

(Also see "[Gene Therapy: What To Expect Now And In The Future](#)" - Scrip, 11 Aug, 2023.)

[Click here to explore this interactive content online](#) ✨